Normal Dynamic MRI Enhancement Patterns of the Upper Abdominal Organs: Gadoxetic Acid Compared With Gadobutrol
- 1 November 2009
- journal article
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 193 (5) , 1318-1323
Abstract
OBJECTIVE. The purpose of this study was to investigate whether, at dynamic MRI of the upper abdominal organs, contrast enhancement with gadoxetic acid, a hepatobiliary contrast agent, is comparable with that achieved with an extracellular contrast agent. SUBJECTS AND METHODS. Dynamic gadoxetic acid–enhanced MRI of the pancreas, spleen, kidney, liver, and abdominal aorta was performed on 50 patients; dynamic gadobutrol–enhanced MRI was performed on a control group of 50 patients; and the images were compared. Dynamic imaging with a T1-weighted volumetric interpolated breath-hold examination gradient-echo sequence (TR/TE, 3.35/1.35; flip angle, 12°) was performed before and 20 (arterial phase), 55 (portal venous phase), and 90 (hepatic venous phase) seconds after bolus injection of gadoxetic acid (0.25 mmol/mL) or gadobutrol (1.0 mmol/mL). Signal-to-noise ratios and enhancement indexes were calculated for each organ and time. RESULTS. All MR images in both groups were of diagnostic quality. During the early dynamic phases, significantly lower mean enhancement indexes were found in the gadoxetic acid group than in the gadobutrol group in the pancreas (portal venous phase, 0.66, 1.39, p ≤ 0.001; hepatic venous phase, 0.51, 1.36, p ≤ 0.001), spleen (portal venous phase, 1.54, 2.41, p ≤ 0.001; hepatic venous phase, 1.19, 2.23, p ≤ 0.001), renal cortex (portal venous phase, 1.76, 2.63, p ≤ 0.001; hepatic venous phase, 1.60, 2.63, p ≤ 0.001), and liver (portal venous phase, 0.76, 0.94, p = 0.016; hepatic venous phase, 0.76, 1.04, p ≤ 0.001). In the abdominal aorta, the mean enhancement index was greater after bolus injection of gadoxetic acid (arterial phase, 3.33, 2.24, p ≤ 0.005). CONCLUSION. Early dynamic MRI of the upper abdominal organs, especially the spleen, pancreas, and kidney, benefits from the higher gadolinium concentration of gadobutrol than in the organ-specific contrast agent gadoxetic acid. Higher protein binding resulting in increased relaxivity of gadoxetic acid compensates for the low gadolinium concentration in the abdominal aorta.Keywords
This publication has 25 references indexed in Scilit:
- Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesionsEuropean Radiology, 2007
- Diagnostic Performance of Gadobenate Dimeglumine–Enhanced MR Angiography of the Iliofemoral and Calf Arteries: A Large-Scale Multicenter TrialAmerican Journal of Roentgenology, 2007
- Dynamic and delayed contrast enhancement in upper abdominal MRI studies: Comparison of gadoxetic acid and gadobutrolEuropean Journal of Radiology, 2007
- Contrast-enhanced MR angiography in rats with hepatobiliary contrast agentsMagnetic Resonance Imaging, 2004
- Currently used non-specific extracellular MR contrast mediaEuropean Radiology, 2003
- Assessment of Gadobenate Dimeglumine for Magnetic Resonance AngiographyInvestigative Radiology, 2002
- Renales Anreicherungsverhalten und Elimination des hepatobiliären Kontrastmittels Gd-EOB-DTPA in der MagnetresonanztomographieRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 2001
- Gadolinium Chelates with Weak Binding to Serum ProteinsInvestigative Radiology, 1997
- Comparison of Gd‐EOB‐DTPA and Gd‐DTPA for contrast‐enhanced MR imaging of liver tumorsJournal of Magnetic Resonance Imaging, 1993
- A new lipophilic gadolinium chelate as a tissue‐specific contrast medium for MRIMagnetic Resonance in Medicine, 1991